Anti-hair loss is a high-potential staple segment in hair care, with strong repurchase rates, healthy margins and broad audience reach — making it a popular entry point for brands building performance hair care lines. Yet it is also a high-risk category for compliance. Overreaching claims about hair growth or alopecia treatment can lead to product delisting, heavy fines or account suspension, especially for export brands navigating divergent rules across markets.
Regulatory standards for hair loss and hair growth claims differ dramatically across China, the EU, the US and ASEAN. Brands must clearly define which claims are permitted for cosmetics and which cross into drug territory before product launch.
1. China: Strict Separation of General vs. Special Cosmetics
China operates a classified regulatory system for hair loss and hair growth products, with very clear boundaries:
1,Allowed for general cosmetics: Strengthen hair roots, reduce hair breakage, fortify hair strands, nourish scalp, support scalp health, improve fragile and easily broken hair.
2.Prohibited red lines: Terms such as “anti-hair loss”, “hair growth”, “hair regrowth”, “promote hair growth” and “activate follicles” are classified as special hair-growth cosmetic claims, requiring special cosmetic registration. Statements involving disease treatment, such as “cure hair loss” or “improve seborrheic alopecia”, directly cross into drug territory.
3.Common pitfall: General shampoo product pages using keywords like “anti-hair loss” or implying hair loss benefits through phrases like “reduce shedding” are considered non-compliant.
2. EU: Claims Require Scientific Evidence, Medical Attributes Are Banned
Under the EC 1223/2009 Cosmetics Regulation, hair-loss related claims are permitted for cosmetics, but must be supported by solid scientific evidence and submitted with CPNP notification:
Allowed cosmetic claims: Reduce hair fall, strengthen hair follicles, support healthy hair growth, improve hair resistance to breakage.
Prohibited red lines: Claims to cure alopecia, medical-grade hair loss treatment, or regrow hair on bald scalp are forbidden. Pharmaceutical ingredients such as minoxidil and finasteride are prohibited in cosmetic formulas.
Key note: All efficacy claims must be backed by human clinical test data. Claims based solely on ingredient mechanism theory are not accepted by regulators.
3. US: Strictest Boundaries – “Anti-Hair Loss” Easily Crosses Into Drug Territory
The FDA maintains an extremely strict line between cosmetics and drugs, making this the highest-risk market for export brands:
1.Allowed cosmetic claims: Improve the appearance of thinning hair, make hair look thicker / fuller, nourish and soothe scalp, reduce hair breakage.
2.Prohibited red lines: Terms such as “anti-hair loss”, “prevent hair loss”, “grow hair” and “hair regrowth” are strictly prohibited. The FDA classifies any product claiming to alter the physiological process of hair growth, stop hair loss or stimulate new growth as a drug, requiring drug approval. Non-compliant products face warning letters, mandatory recalls and even store shutdowns.
3.Common pitfall: Many Chinese brands directly translate “防脱” as “anti-hair loss” and list it on marketplaces like Amazon, easily triggering FDA compliance reviews, listing removal and fund holds.
4. ASEAN: Harmonized Rules With Varying National Enforcement
ASEAN follows the ASEAN Cosmetic Directive (ACD), with claim logic broadly similar to the EU, but varying enforcement intensity across member states:
1.Allowed cosmetic claims: Reduce hair breakage, strengthen hair roots, maintain healthy scalp environment, nourish hair follicles.
2.Prohibited red lines: Medical claims to treat hair loss, stimulate hair growth or cure baldness are forbidden. Markets such as Thailand and the Philippines are tightening scrutiny of hair-loss related language, requiring supporting efficacy documentation.
3.Key note: The Indonesian market requires additional halal certification consideration. Malaysia and Singapore generally enforce stricter efficacy claim compliance.
3 Most Common Compliance Mistakes Brands Make
1.Ingredient mechanism ≠ permitted product claim: Even if an ingredient has supporting research, brands cannot directly conclude the product delivers “anti-hair loss” or “hair growth” effects. In strict markets like the US, only visual appearance improvements may be described, not physiological effects.
2.Direct translation creates compliance risk: Translating Chinese “防脱” directly as “anti-hair loss” requires efficacy data in the EU, and classifies the product as a drug in the US. Export brands must adapt wording to local rules.
3.Platform rules are stricter than regulations: Internal review standards on marketplaces like Amazon, Temu and Shopee are often tighter than local regulations. Even marginally acceptable claims under law can result in immediate delisting.
MOOYAM OEM Anti-Hair Loss Compliance Customization
The anti-hair loss segment offers major opportunities, but compliance is the entry prerequisite. MOOYAM OEM has a dedicated global compliance team with deep expertise in cosmetic regulations across China, the EU, the US and ASEAN. We provide end-to-end services including formula compliance review, claim language guidance and filing documentation support, helping hair care brands enter the anti-hair loss segment safely and efficiently.
